- Home
- RMCO vs VERU Comparison
RMCO vs VERU Comparison
Compare RMCO & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMCO
- VERU
- Stock Information
- Founded
- RMCO 2021
- VERU 1971
- Country
- RMCO United States
- VERU United States
- Employees
- RMCO N/A
- VERU N/A
- Industry
- RMCO Multi-Sector Companies
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- RMCO Miscellaneous
- VERU Health Care
- Exchange
- RMCO Nasdaq
- VERU Nasdaq
- Market Cap
- RMCO 45.7M
- VERU 54.6M
- IPO Year
- RMCO N/A
- VERU 1990
- Fundamental
- Price
- RMCO $3.04
- VERU $3.81
- Analyst Decision
- RMCO Buy
- VERU Strong Buy
- Analyst Count
- RMCO 1
- VERU 3
- Target Price
- RMCO N/A
- VERU $33.33
- AVG Volume (30 Days)
- RMCO 165.1K
- VERU 138.1K
- Earning Date
- RMCO 11-14-2025
- VERU 08-12-2025
- Dividend Yield
- RMCO 0.32%
- VERU N/A
- EPS Growth
- RMCO N/A
- VERU N/A
- EPS
- RMCO N/A
- VERU N/A
- Revenue
- RMCO $2,641,171.00
- VERU $16,886,419.00
- Revenue This Year
- RMCO N/A
- VERU N/A
- Revenue Next Year
- RMCO N/A
- VERU N/A
- P/E Ratio
- RMCO N/A
- VERU N/A
- Revenue Growth
- RMCO 292.46
- VERU 337.24
- 52 Week Low
- RMCO $0.90
- VERU $2.64
- 52 Week High
- RMCO $4.76
- VERU $14.20
- Technical
- Relative Strength Index (RSI)
- RMCO 53.92
- VERU 49.82
- Support Level
- RMCO $2.80
- VERU $3.69
- Resistance Level
- RMCO $4.29
- VERU $4.33
- Average True Range (ATR)
- RMCO 0.52
- VERU 0.33
- MACD
- RMCO -0.05
- VERU -0.08
- Stochastic Oscillator
- RMCO 14.29
- VERU 17.78
About RMCO Royalty Management Holding Corporation
Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.